The European Medicines Agency has approved a major update for subcutaneous daratumumab, allowing it to become the first cancer injectable in Europe that patients can administer themselves at home.
This change means that patients with multiple myeloma, or their caregivers, can give the treatment outside of a hospital starting from the fifth dose, as long as they are properly trained and approved by a doctor. The update applies to all previously approved uses of the drug, including newly diagnosed, relapsed, and hard-to-treat cases, as well as light chain amyloidosis.
The move is expected to reduce the need for frequent hospital visits, giving patients more independence while also easing pressure on healthcare systems. By the end of 2025, daratumumab had already been used in more than 748,000 patients worldwide, showing its widespread role in treatment.
To switch to home use, patients must first complete four doses in a clinical setting, receive approval from a healthcare professional, and undergo proper training on how to perform the injection safely.